Pharmaceutical Technology

FEBRUARY 13, 2023

The first concept for a PROTAC was published in 2001, and recently these protein degraders have gained rapid momentum as a promising novel modality. This makes early R&D less risky, as many lead compounds are discontinued due to inadequate pharmacokinetic profiles and require excessively high dosages to be pharmaceutically active.

Dosage 59

Dosage Chemotherapy Compounding Immunization 59

The Thyroid Pharmacist

NOVEMBER 4, 2022

While the human body (via the liver and kidneys) can produce up to 4 g/day of inositol, it has been found that the overly processed, high glucose (and low fiber) Western diets that many people follow, only provide about 1 g/day of the compound. (7). Some people actually went into remission after starting the myo-inositol. Endokrynol Pol.

Dosage 98

Dosage Compounding Immunization Chemotherapy 98

The FDA Law Blog

FEBRUARY 11, 2024

Not surprisingly, then-presidential candidate Asa Hutchinson, DEA Administrator from 2001 to 2003, did not sign the letter. The letter is signed by six former DEA administrators and five former Directors of National Drug Policy. The earliest tenured is John Bartels, who served as Administrator from 1973 to 1975.

Controlled Substances 59

Controlled Substances Chemotherapy Compounding FDA 59